文献速递银屑病与炎症性皮肤病

美国门诊成人银屑病与非酒精性脂肪性肝病的关联

Association Between Psoriasis and Nonalcoholic Fatty Liver Disease Among Outpatient US Adults.
PubMed 文献 · JAMA Dermatol · 2022-01-01

这项基于美国国家健康与营养调查(NHANES)2003-2006及2009-2014周期的横断面研究纳入5672名20-59岁美国成人,采用美国脂肪肝指数>30定义非酒精性脂肪性肝病(NAFLD)。多变量logistic回归显示银屑病与NAFLD相关(OR 1.67,95% CI 1.03-2.70),该关联在多项敏感性分析中仍存在。

要点

  • 银屑病患者NAFLD患病率为32.7%(52例),无银屑病者为26.6%(1506例)。
  • 多变量调整后银屑病与NAFLD相关(OR 1.67,95% CI 1.03-2.70)。
  • 男性、20-39岁及无糖尿病亚组中银屑病与NAFLD的关联仍存在。

核心结论

  • 在美国门诊成人中,调整后模型显示银屑病与NAFLD相关。
  • 作者认为,临床医生为银屑病管理开具潜在肝毒性药物时,应考虑这一关联。

研究设计与样本

  • 基于人群的横断面研究,使用美国国家健康与营养调查(NHANES)2003-2006和2009-2014周期中20-59岁美国成人数据。
  • 共纳入5672名成人(平均年龄38.9岁,95% CI 38.4-39.3岁;2999名女性,占51.1%)。
  • 银屑病通过自我报告确定;NAFLD定义为美国脂肪肝指数评分大于30。
  • 数据分析时间为2021年6月至9月。

主要发现

  • 5672名成人中148名(3.0%)有银屑病,5524名(97.0%)无银屑病;1558名参与者(26.8%)被归类为NAFLD。
  • 银屑病组NAFLD患病率为32.7%(52例),无银屑病组为26.6%(1506例)。
  • 多变量logistic回归调整年龄、性别、种族和民族、教育水平、家庭收入、婚姻状况、NHANES周期、糖尿病、代谢综合征及吸烟饮酒状态后,银屑病与NAFLD相关(OR 1.67,95% CI 1.03-2.70)。
  • 亚组分析中,银屑病与NAFLD在男性(OR 2.16,95% CI 1.10-4.24)、20-39岁人群(OR 2.48,95% CI 1.09-5.67)及无糖尿病者(OR 1.70,95% CI 1.05-2.76)中相关。
  • 敏感性分析中,排除潜在肝毒性药物使用(OR 1.72,95% CI 1.01-2.95)或非西班牙裔黑人参与者(OR 1.76,95% CI 1.07-2.87)、基于肝脂肪变性指数评分重新定义NAFLD(OR 1.59,95% CI 1.01-2.50)以及使用逆概率治疗加权(OR 1.43,95% CI 1.09-1.86)时,银屑病与NAFLD的关联仍存在。

关键数值与推荐

  • NAFLD定义为美国脂肪肝指数评分大于30。
  • 银屑病与NAFLD的关联在多变量调整模型中OR为1.67(95% CI 1.03-2.70)。
  • 男性亚组OR为2.16(95% CI 1.10-4.24)。
  • 20-39岁亚组OR为2.48(95% CI 1.09-5.67)。
  • 无糖尿病亚组OR为1.70(95% CI 1.05-2.76)。

临床怎么用

  • 作者认为,临床医生为银屑病管理开具潜在肝毒性药物时,应考虑银屑病与NAFLD的关联。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Recent studies have shown an association between psoriasis and nonalcoholic fatty liver disease (NAFLD) in US inpatients, but the association is still unclear in the outpatient US population. OBJECTIVE: To assess whether psoriasis is associated with NAFLD in outpatient US adults. DESIGN, SETTING, AND PARTICIPANTS: This population-based cross-sectional study used data on US adults aged 20 to 59 years from the National Health and Nutrition Examination Survey (NHANES) 2003-2006 and 2009-2014 cycles. Data were analyzed from June to September 2021. EXPOSURES: Self-reported psoriasis. MAIN OUTCOMES AND MEASURES: The main outcome was NAFLD, defined as a US fatty liver index score greater than 30. Sampling weights were calculated according to NHANES guidelines. RESULTS: Among 5672 adults included in this study (mean age, 38.9 years [95% CI, 38.4-39.3 years]; 2999 [51.1%] female), 148 (3.0%) had psoriasis and 5524 (97.0%) did not have psoriasis. A total of 1558 participants (26.8%) were classified as having NAFLD. Compared with participants without psoriasis, those with psoriasis had a higher prevalence of NAFLD (32.7% [52] vs 26.6% [1506]). In a multivariable logistic regression model adjusted for age, sex, race and ethnicity, educational level, family income, marital status, NHANES cycles, diabetes, metabolic syndrome, and smoking and alcohol drinking status, psoriasis was associated with NAFLD (odds ratio [OR], 1.67; 95% CI, 1.03-2.70). In subgroup analyses, psoriasis was associated with NAFLD among men (OR, 2.16; 95% CI, 1.10-4.24), among those aged 20 to 39 years (OR, 2.48; 95% CI, 1.09-5.67), and among those without diabetes (1.70; 95% CI, 1.05-2.76). An association between psoriasis and NAFLD was found in sensitivity analyses that excluded potential hepatotoxic medication use (OR, 1.72; 95% CI, 1.01-2.95) or non-Hispanic Black participants (OR, 1.76; 95% CI, 1.07-2.87), redefined NAFLD based on the hepatic steatosis index score (OR, 1.59; 95% CI, 1.01-2.50), and used inverse probability of treatment weighting (OR, 1.43; 95% CI, 1.09-1.86). CONCLUSIONS AND RELEVANCE: In this cross-sectional study, psoriasis was associated with NAFLD in the outpatient US adult population in adjusted models. This association may be important to consider in the context of clinicians prescribing potentially hepatotoxic medication for psoriasis management.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Ruan Z, Lu T, Chen Y, et al. Association Between Psoriasis and Nonalcoholic Fatty Liver Disease Among Outpatient US Adults. JAMA Dermatol. 2022. PMID: 35612851. doi:10.1001/jamadermatol.2022.1609

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。